Skip to main content
Top
Published in: BMC Infectious Diseases 1/2022

Open Access 01-12-2022 | SARS-CoV-2 | Research

Retrospective analysis of SARS-CoV-2 omicron invasion over delta in French regions in 2021–22: a status-based multi-variant model

Authors: Thomas Haschka, Elisabeta Vergu, Benjamin Roche, Chiara Poletto, Lulla Opatowski

Published in: BMC Infectious Diseases | Issue 1/2022

Login to get access

Abstract

Background

SARS-CoV-2 is a rapidly spreading disease affecting human life and the economy on a global scale. The disease has caused so far more then 5.5 million deaths. The omicron outbreak that emerged in Botswana in the south of Africa spread around the globe at further increased rates, and caused unprecedented SARS-CoV-2 infection incidences in several countries. At the start of December 2021 the first omicron cases were reported in France.

Methods

In this paper we investigate the spreading potential of this novel variant relatively to the delta variant that was also in circulation in France at that time. Using a dynamic multi-variant model accounting for cross-immunity through a status-based approach, we analyze screening data reported by Santé Publique France over 13 metropolitan French regions between 1st of December 2021 and the 30th of January 2022. During the investigated period, the delta variant was replaced by omicron in all metropolitan regions in approximately three weeks. The analysis conducted retrospectively allows us to consider the whole replacement time window and compare regions with different times of omicron introduction and baseline levels of variants’ transmission potential. As large uncertainties regarding cross-immunity among variants persist, uncertainty analyses were carried out to assess its impact on our estimations.

Results

Assuming that 80% of the population was immunized against delta, a cross delta/omicron cross-immunity of 25% and an omicron generation time of 3.5 days, the relative strength of omicron to delta, expressed as the ratio of their respective reproduction rates, \(\frac{\hat{R}_{\textrm{omicron}}}{\hat{R}_{\textrm{delta}}}\), was found to range between 1.51 and 1.86 across regions. Uncertainty analysis on epidemiological parameters led to \(\frac{\hat{R}_{\textrm{omicron}}}{\hat{R}_{\textrm{delta}}}\) ranging from 1.57 to 2.34 on average over the metropolitan French regions, weighted by population size.

Conclusions

Upon introduction, omicron spread rapidly through the French territory and showed a high fitness relative to delta. We documented considerable geographical heterogeneities on the spreading dynamics. The historical reconstruction of variant emergence dynamics provide valuable ground knowledge to face future variant emergence events.
Appendix
Available only for authorised users
Literature
2.
go back to reference Viana R, Moyo S, Amoako DG, Tegally H, Scheepers C, Althaus CL, Anyaneji UJ, Bester PA, Boni MF, Chand M, Choga WT, Colquhoun R, Davids M, Deforche K, Doolabh D, Engelbrecht S, Everatt J, Giandhari J, Giovanetti M, Hardie D, Hill V, Hsiao N-Y, Iranzadeh A, Ismail A, Joseph C, Joseph R, Koopile L, Pond SLK, Kraemer MU, Kuate-Lere L, Laguda-Akingba O, Lesetedi-Mafoko O, Lessells RJ, Lockman S, Lucaci AG, Maharaj A, Mahlangu B, Maponga T, Mahlakwane K, Makatini Z, Marais G, Maruapula D, Masupu K, Matshaba M, Mayaphi S, Mbhele N, Mbulawa MB, Mendes A, Mlisana K, Mnguni A, Mohale T, Moir M, Moruisi K, Mosepele M, Motsatsi G, Motswaledi MS, Mphoyakgosi T, Msomi N, Mwangi PN, Naidoo Y, Ntuli N, Nyaga M, Olubayo L, Pillay S, Radibe B, Ramphal Y, Ramphal U, San JE, Scott L, Shapiro R, Singh L, Smith-Lawrence P, Stevens W, Strydom A, Subramoney K, Tebeila N, Tshiabuila D, Tsui J, van Wyk S, Weaver S, Wibmer CK, Wilkinson E, Wolter N, Zarebski AE, Zuze B, Goedhals D, Preiser W, Treurnicht F, Venter M, Williamson C, Pybus OG, Bhiman J, Glass A, Martin DP, Rambaut A, Gaseitsiwe S, von Gottberg A, de Oliveira T. Rapid epidemic expansion of the sars-cov-2 omicron variant in Southern Africa. medRxiv. 2021. https://doi.org/10.1101/2021.12.19.21268028.CrossRef Viana R, Moyo S, Amoako DG, Tegally H, Scheepers C, Althaus CL, Anyaneji UJ, Bester PA, Boni MF, Chand M, Choga WT, Colquhoun R, Davids M, Deforche K, Doolabh D, Engelbrecht S, Everatt J, Giandhari J, Giovanetti M, Hardie D, Hill V, Hsiao N-Y, Iranzadeh A, Ismail A, Joseph C, Joseph R, Koopile L, Pond SLK, Kraemer MU, Kuate-Lere L, Laguda-Akingba O, Lesetedi-Mafoko O, Lessells RJ, Lockman S, Lucaci AG, Maharaj A, Mahlangu B, Maponga T, Mahlakwane K, Makatini Z, Marais G, Maruapula D, Masupu K, Matshaba M, Mayaphi S, Mbhele N, Mbulawa MB, Mendes A, Mlisana K, Mnguni A, Mohale T, Moir M, Moruisi K, Mosepele M, Motsatsi G, Motswaledi MS, Mphoyakgosi T, Msomi N, Mwangi PN, Naidoo Y, Ntuli N, Nyaga M, Olubayo L, Pillay S, Radibe B, Ramphal Y, Ramphal U, San JE, Scott L, Shapiro R, Singh L, Smith-Lawrence P, Stevens W, Strydom A, Subramoney K, Tebeila N, Tshiabuila D, Tsui J, van Wyk S, Weaver S, Wibmer CK, Wilkinson E, Wolter N, Zarebski AE, Zuze B, Goedhals D, Preiser W, Treurnicht F, Venter M, Williamson C, Pybus OG, Bhiman J, Glass A, Martin DP, Rambaut A, Gaseitsiwe S, von Gottberg A, de Oliveira T. Rapid epidemic expansion of the sars-cov-2 omicron variant in Southern Africa. medRxiv. 2021. https://​doi.​org/​10.​1101/​2021.​12.​19.​21268028.CrossRef
4.
go back to reference Organization WH, et al. COVID-19 weekly epidemiological update, edition 70, 2021;2021. Organization WH, et al. COVID-19 weekly epidemiological update, edition 70, 2021;2021.
10.
go back to reference Lundberg AL, Lorenzo-Redondo R, Ozer EA, Hawkins CA, Hultquist JF, Welch SB, Prasad PV, Oehmke JF, Achenbach CJ, Murphy RL, White JI, Havey RJ, Post LA. Has omicron changed the evolution of the pandemic? JMIR Public Health Surveill. 2022;8(1):35763. https://doi.org/10.2196/35763.CrossRef Lundberg AL, Lorenzo-Redondo R, Ozer EA, Hawkins CA, Hultquist JF, Welch SB, Prasad PV, Oehmke JF, Achenbach CJ, Murphy RL, White JI, Havey RJ, Post LA. Has omicron changed the evolution of the pandemic? JMIR Public Health Surveill. 2022;8(1):35763. https://​doi.​org/​10.​2196/​35763.CrossRef
11.
go back to reference France SP. COVID-19: Point épidémiologique hebdomadaire du 2021. Santé Publique France 2021. France SP. COVID-19: Point épidémiologique hebdomadaire du 2021. Santé Publique France 2021.
13.
go back to reference Mazzoli M, Di Domenico L, EMERGEN-Consortium, Colizza V. Early assessment of the omicron variant’s presence and growth rate in regions of France. Epix-lab reports 2021;(35). Mazzoli M, Di Domenico L, EMERGEN-Consortium, Colizza V. Early assessment of the omicron variant’s presence and growth rate in regions of France. Epix-lab reports 2021;(35).
14.
go back to reference Andronico, Alessio and Tran Kiem, Cécile and Bosetti, Paolo and Paireau, Juliette: Impact du variant omicron sur l’épidémie covid-19 et son contrôle en france métropolitaine durant l’hiver 2021–2022. 2021. Andronico, Alessio and Tran Kiem, Cécile and Bosetti, Paolo and Paireau, Juliette: Impact du variant omicron sur l’épidémie covid-19 et son contrôle en france métropolitaine durant l’hiver 2021–2022. 2021.
15.
go back to reference France SP. COVID-19: Point épidémiologique hebdomadaire du 2022. Santé Publique France 2022. France SP. COVID-19: Point épidémiologique hebdomadaire du 2022. Santé Publique France 2022.
16.
17.
go back to reference Gangavarapu K, Latif AA, Mullen JL, Alkuzweny M, Hufbauer E, Tsueng G, Haag E, Zeller M, Aceves CM, Zaiets K, Cano M, Zhou J, Qian Z, Sattler R, Matteson NL, Levy JI, Lee RT, Freitas L, Maurer-Stroh S, Suchard MA, Wu C, Su AI, Andersen KG, Hughes LD. French Variant Report: outbreak.info accessed 19 September 2022. https://outbreak.info/location-reports?loc=FRA. 2022. Gangavarapu K, Latif AA, Mullen JL, Alkuzweny M, Hufbauer E, Tsueng G, Haag E, Zeller M, Aceves CM, Zaiets K, Cano M, Zhou J, Qian Z, Sattler R, Matteson NL, Levy JI, Lee RT, Freitas L, Maurer-Stroh S, Suchard MA, Wu C, Su AI, Andersen KG, Hughes LD. French Variant Report: outbreak.info accessed 19 September 2022. https://​outbreak.​info/​location-reports?​loc=​FRA.​ 2022.
18.
go back to reference Khare, S., Gurry, C., Freitas, L., Schultz, M.B., Bach, G., Diallo, A., Akite, N., Ho, J., Lee, R.T., Yeo, W., Curation Team, G.C., Maurer-Stroh, S. GISAID’s role in pandemic response. China CDC Wkly. 2021;3(49):1049–51.CrossRef Khare, S., Gurry, C., Freitas, L., Schultz, M.B., Bach, G., Diallo, A., Akite, N., Ho, J., Lee, R.T., Yeo, W., Curation Team, G.C., Maurer-Stroh, S. GISAID’s role in pandemic response. China CDC Wkly. 2021;3(49):1049–51.CrossRef
19.
go back to reference Sofonea MT, Roquebert B, Foulongne V, Morquin D, Verdurme L, Trombert-Paolantoni S, Roussel M, Bonetti J-C, Zerah J, Haim-Boukobza S, Alizon S. Analyzing and modeling the spread of SARS-CoV-2 omicron lineages BA1 and BA2, France, September 2021-February 2022. Emerg Infect Dis. 2022;28(7):1355–65.CrossRefPubMedPubMedCentral Sofonea MT, Roquebert B, Foulongne V, Morquin D, Verdurme L, Trombert-Paolantoni S, Roussel M, Bonetti J-C, Zerah J, Haim-Boukobza S, Alizon S. Analyzing and modeling the spread of SARS-CoV-2 omicron lineages BA1 and BA2, France, September 2021-February 2022. Emerg Infect Dis. 2022;28(7):1355–65.CrossRefPubMedPubMedCentral
20.
go back to reference Mazzoli M, Di Domenico L, EMERGEN-Consortium, Colizza V. Assessment of the omicron ba.2 sub-lineage presence and growth rate in regions of France. Epix-lab reports. 2022;36. Mazzoli M, Di Domenico L, EMERGEN-Consortium, Colizza V. Assessment of the omicron ba.2 sub-lineage presence and growth rate in regions of France. Epix-lab reports. 2022;36.
22.
go back to reference France SP. Communiqué de presse: Variant omicron: quelle surveillance mise en place? 2021. France SP. Communiqué de presse: Variant omicron: quelle surveillance mise en place? 2021.
24.
go back to reference Jones TC, Biele G, Mühlemann B, Veith T, Schneider J, Beheim-Schwarzbach J, Bleicker T, Tesch J, Schmidt ML, Sander LE, Kurth F, Menzel P, Schwarzer R, Zuchowski M, Hofmann J, Krumbholz A, Stein A, Edelmann A, Corman VM, Drosten C. Estimating infectiousness throughout sars-cov-2 infection course. Science. 2021;373(6551):5273. https://doi.org/10.1126/science.abi5273.CrossRef Jones TC, Biele G, Mühlemann B, Veith T, Schneider J, Beheim-Schwarzbach J, Bleicker T, Tesch J, Schmidt ML, Sander LE, Kurth F, Menzel P, Schwarzer R, Zuchowski M, Hofmann J, Krumbholz A, Stein A, Edelmann A, Corman VM, Drosten C. Estimating infectiousness throughout sars-cov-2 infection course. Science. 2021;373(6551):5273. https://​doi.​org/​10.​1126/​science.​abi5273.CrossRef
Metadata
Title
Retrospective analysis of SARS-CoV-2 omicron invasion over delta in French regions in 2021–22: a status-based multi-variant model
Authors
Thomas Haschka
Elisabeta Vergu
Benjamin Roche
Chiara Poletto
Lulla Opatowski
Publication date
01-12-2022
Publisher
BioMed Central
Keyword
SARS-CoV-2
Published in
BMC Infectious Diseases / Issue 1/2022
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-022-07821-5

Other articles of this Issue 1/2022

BMC Infectious Diseases 1/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine